A Study in Patients With Advanced Breast Cancer

Summary

A Phase 1, Open label, Dose escalation and Dose expansion study of SCO-120 in HR +ve HER2-ve advanced/ metastatic breast cancer (MBC) patients to evalaute the safety, tolerability and prelimnary efficacy. Initial part with dose escalation is to determine the MTD and RP2D, and PK and PD characterisation. RP2D will be further evalauted for prelimnary efficacy in MBC patients with tretament failure on Aromatase Inhibitor/Fulvestrant/CDK4-6 inhibitors with or with out ESR1 mutation.

Timeline

Start

2022-05-20

Primary completion

2023-02-28

Completion

2023-02-28

Outcome

Outcome not reported

Stopped: “The decision to close is due commercial reasons only”

Drugs

Indications